Repligen Corporation, founded in 1981 by Alexander Rich and Paul Schimmel, is a public bioprocessing company headquartered in Waltham, Massachusetts. The company's core mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide. Repligen focuses on developing, producing, and commercializing innovative products for manufacturing biologic drugs, serving life sciences companies, global biopharmaceutical firms, and contract manufacturers.
Notable figures associated with Repligen include its founders and key personnel like Tony J. The company is publicly traded on Nasdaq under the symbol RGEN and is a component of the S&P 400. Repligen has achieved significant milestones in bioprocessing innovation, simplifying complex workflows, and maximizing productivity. Its impact on the pharmaceutical industry is marked by its commitment to pushing the boundaries of what's possible in biologic drug manufacturing.
